Inogen IncINGNEarnings & Financial Report
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
Revenue
$74.4M
Gross Profit
$42.7M
Operating Profit
$-7.1M
Net Profit
$-5.6M
Gross Margin
57.4%
Operating Margin
-9.5%
Net Margin
-7.5%
YoY Growth
8.9%
EPS
$-0.24
Inogen Inc Q2 FY2024 Financial Summary
Inogen Inc reported revenue of $74.4M (up 8.9% YoY) for Q2 FY2024, with a net profit of $-5.6M (up 43.1% YoY) (-7.5% margin). Cost of goods sold was $31.7M, operating expenses totaled $49.8M.
Key Financial Metrics
| Total Revenue | $74.4M |
|---|---|
| Net Profit | $-5.6M |
| Gross Margin | 57.4% |
| Operating Margin | -9.5% |
| Report Period | Q2 FY2024 |
Inogen Inc Annual Revenue by Year
Inogen Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $295.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $295.3M |
| 2024 | $278.8M |
| 2023 | $251.6M |
| 2022 | $320.5M |
Inogen Inc Quarterly Revenue & Net Profit History
Inogen Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $68.6M | +3.4% | N/A | N/A |
| Q3 FY2025 | $79.1M | +5.6% | $-5.3M | -6.7% |
| Q2 FY2025 | $79.2M | +6.4% | $-4.2M | -5.2% |
| Q1 FY2025 | $68.5M | +8.5% | $-6.2M | -9.0% |
| Q4 FY2024 | $66.3M | +11.6% | N/A | N/A |
| Q3 FY2024 | $74.9M | +10.2% | $-6.0M | -8.0% |
| Q2 FY2024 | $74.4M | +8.9% | $-5.6M | -7.5% |
| Q1 FY2024 | $63.1M | +12.9% | $-14.6M | -23.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.1M | $74.4M | $74.9M | $66.3M | $68.5M | $79.2M | $79.1M | $68.6M |
| YoY Growth | 12.9% | 8.9% | 10.2% | 11.6% | 8.5% | 6.4% | 5.6% | 3.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $315.6M | $308.9M | $306.2M | $296.2M | $308.4M | $312.0M | $307.0M | $298.6M |
| Liabilities | $123.7M | $121.3M | $120.8M | $122.3M | $110.5M | $112.5M | $109.8M | $106.4M |
| Equity | $191.9M | $187.6M | $185.4M | $173.9M | $198.0M | $199.5M | $197.2M | $192.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.7M | $6.7M | $7.0M | $-3.0M | $-16.8M | $4.3M | $2.2M | $-943000 |